Key facts
- Amphix Bio’s last known valuation is $39.0M (Dec 2025).
- It has raised $16.3M across 1 recorded rounds; the latest was Early Stage VC ($10.3M) in Dec 2025.
- Notable investors include US National Science Foundation, Christopher & Dana Reeve Foundation, Northwestern University.
- Amphix Bio has filed 1 Form D with the SEC, most recently Dec 2025 ($10.3M sold to 9 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Amphix Bio
Funding rounds
1 roundsAbout Amphix Bio
Developer of a therapeutic peptide platform designed to drive regenerative medicine by restoring function lost to injury, disease, or aging. The company offers supramolecular peptides that modulate immune response, activate targeted signaling pathways, and form biological scaffolds, enabling clinicians and researchers in musculoskeletal and central nervous system care to support tissue repair and functional recovery.
- Sector
- Healthcare
- HQ
- Chicago, IL, United States
- Founded
- 2019
- Employees
- 7
- Website
- amphixbio.com/
- Ownership
- Privately Held (backing)
Amphix Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Amphix Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Amphix Bio in its N-PORT filings yet. We sweep new filings monthly.